Ad
Monday, 3 December 2018
Dutch firm argenx, J&J affiliate to collaborate on cancer therapy
Netherlands-based biopharmaceutical company argenx SE said it signed a deal with Cilag GmbH International, an affiliate of Johnson & Johnson's Janssen Pharmaceutical Companies unit, to develop its Cusatuzumab drug in certain types of cancer.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment